Oxford, UK – 5 October 2015 – OxSonics Limited (“OxSonics”), University of Oxford spin-out company developing a new generation of ultrasound-based medical devices, today announced it had won the award for the “Best Emerging UK Medtech Company” at the OBN annual award ceremony.
The awards celebrate the key achievements within the UK’s bioscience and medical technology sector over the past year.
The independent judging panel consisted of 11 representatives from Biotech, Pharma, VC, and Corporate VC. The panel considered OxSonics the best emerging UK medtech company for the following reasons:
“Great management team”
“Making rapid progress with the development of highly disruptive technology in the oncology field”
“Technology being developed is likely to have a significant impact on the effectiveness of cancer treatments”
Dr Colin Story, Chief Executive Officer commented: “We are delighted to have secured this prestigious award. We have made tremendous strides towards our goal of delivering life changing therapies to cancer patients during the past year. This award not only recognises the novelty and innovation underpinning our technology but also the dedication and commitment of the entire OxSonics team.”
- ENDS -
About OxSonics Limited
OxSonics was established in July 2013 to develop and commercialise ground-breaking advancements in the field of therapeutic ultrasound invented at the University of Oxford’s Institute of Biomedical Engineering. OxSonics “SonoTran” drug delivery platform has the capability to overcome one of the greatest challenges facing solid tumour cancer therapy by delivering drugs throughout tumours, including to the areas that lie furthest from blood vessels. SonoTran can be applied to any cancer drug. A major benefit of OxSonics’ technology is the ability to provide real-time on-screen feedback to the clinician as to where and when drug delivery is taking place. OxSonics is based in Oxford, UK. For more information please visit: www.oxsonics.com.
The OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Our 360-plus Member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland benefiting from our networking, partnering, purchasing, advising and advocacy activities. For more information please visit: www.obn.org.uk.